Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trials Optional) (RFA CA 18 010)

 

 

Opportunity Information:

  • The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trials Optional)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
  • This funding opportunity was created on Dec 04, 2017.
  • Applicants must submit their applications by Sep 28, 2018.
  • Each selected applicant is eligible to receive up to $150,000.00 in funding.
  • The number of recipients for this funding is limited to 3 candidate(s).
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).

Applicants also applied for:

Applicants who have applied for this opportunity (RFA CA 18 010) also looked into and applied for these:

Funding Number Funding Title
RFA CA 18 008 Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
RFA CA 18 007 Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trials Optional)
RFA CA 18 006 Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trials Optional)
RFA DA 18 020 NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
PA 18 496 Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed)
RFA DA 18 023 Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed)
RUS 18 01 DLT Distance Learning and Telemedicine Grant Program
PAR 18 752 Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed)

 

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 18 010", eligibility, application service, and/or application tips? Submit an inquiry below:

First Name
Last Name
Email Address
Phone Number

 

Ask a Question:

 

Application Process

Step 1

Self assessment. Grants are available to government, education, public housing, and not for profit organizations. If you are a small business, your business must exceed SBA's size standards.

Step 2

Review the funding details for the opportunity (RFA CA 18 010) and check/verify your eligibility.

Step 3

Register as an individual or as an organization and obtain your grants.gov account.

Step 4

Prepare your application package. Utilize grants.gov's workspace collaboration feature if needed. Submit your application and obtain your unique tracking number.

Step 5

Funding officials will review your application package. Use your tracking number to view and check on the status of your application.

Previous Opportunities